VANADIS® (AKI)
Acute Kidney Injury
Pre-clinicalActive
Key Facts
About CFM Pharma
CFM Pharma is a private, clinical-stage biotech leveraging its patented VANADIS® platform of organovanadium compounds to address significant unmet needs in acute trauma. Its lead candidate, VANADIS® BMOV, has completed Phase 1A safety studies for myocardial infarction and is Phase 1B-ready, with preclinical data showing up to 42% reduction in infarct size. The company is positioning itself for value inflection through clinical readouts and early-stage partnerships, targeting multi-billion dollar markets in cardiology, burn care, and acute kidney injury.
View full company profileTherapeutic Areas
Other Acute Kidney Injury Drugs
| Drug | Company | Phase |
|---|---|---|
| Centhaquine | Pharmazz | Preclinical |
| AKI Program | Keli Therapeutics | Clinical Trial Launch |
| ENT1 Inhibitor | RapaFusyn Pharmaceuticals | Preclinical |
| HGF protein | Kringle Pharma | Phase 1 |